PA8462301A1 - Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa - Google Patents

Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa

Info

Publication number
PA8462301A1
PA8462301A1 PA19988462301A PA8462301A PA8462301A1 PA 8462301 A1 PA8462301 A1 PA 8462301A1 PA 19988462301 A PA19988462301 A PA 19988462301A PA 8462301 A PA8462301 A PA 8462301A PA 8462301 A1 PA8462301 A1 PA 8462301A1
Authority
PA
Panama
Prior art keywords
inhibitor
aldosa
combination
glucogen
reductase
Prior art date
Application number
PA19988462301A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Dennis Jay Hoover
Bernard Hulin
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8462301A1 publication Critical patent/PA8462301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superheterodyne Receivers (AREA)
  • Noise Elimination (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS DE COMBINACION Y PRODCEDIMIENTOS QUE INCLUYEN INHIBIDORES DE LA ALDOSA REDUCTASA E INHIBIDORES DE LA GLUCOGENO FOSFORILASA. LAS COMPOSICIONES Y PROCEDIMIENTOS SON UTILES PARA EL TRATAMIENTO DE AFECCIONES RESISTENTES A INSULINA, TALES COMO LA DIABETES, Y PARA REDUCIR LAS LESIONES TISULARES DEBIDAS A ISQUEMIA.
PA19988462301A 1997-11-21 1998-10-28 Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa PA8462301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21

Publications (1)

Publication Number Publication Date
PA8462301A1 true PA8462301A1 (es) 2000-05-24

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19988462301A PA8462301A1 (es) 1997-11-21 1998-10-28 Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa

Country Status (38)

Country Link
EP (1) EP1032424B9 (es)
JP (1) JP2002504478A (es)
KR (2) KR20010032304A (es)
CN (1) CN1279617A (es)
AP (1) AP911A (es)
AR (1) AR016423A1 (es)
AT (1) ATE205403T1 (es)
AU (1) AU733304B2 (es)
BG (1) BG104435A (es)
BR (1) BR9814698A (es)
CA (1) CA2310069A1 (es)
DE (1) DE69801680T2 (es)
DK (1) DK1032424T3 (es)
DZ (1) DZ2656A1 (es)
EA (1) EA002365B1 (es)
ES (1) ES2161548T3 (es)
GR (1) GR3037071T3 (es)
GT (1) GT199800166A (es)
HR (1) HRP20000327A2 (es)
HU (1) HUP0100272A3 (es)
ID (1) ID24524A (es)
IL (1) IL135713A0 (es)
IS (1) IS5453A (es)
MA (1) MA26568A1 (es)
NO (1) NO20002164L (es)
OA (1) OA11379A (es)
PA (1) PA8462301A1 (es)
PE (1) PE135399A1 (es)
PL (1) PL340643A1 (es)
PT (1) PT1032424E (es)
SK (1) SK7222000A3 (es)
TN (1) TNSN98211A1 (es)
TR (1) TR200001451T2 (es)
UA (1) UA57811C2 (es)
UY (1) UY25258A1 (es)
WO (1) WO1999026659A1 (es)
YU (1) YU30700A (es)
ZA (1) ZA9810636B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2535700A (en) * 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
DK1741445T3 (da) 2000-01-21 2013-11-04 Novartis Ag Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR100918322B1 (ko) 2003-11-12 2009-09-22 페노믹스 코포레이션 헤테로시클릭 보론산 화합물
EP1778220A1 (en) 2004-07-12 2007-05-02 Phenomix Corporation Constrained cyano compounds
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR101352588B1 (ko) 2005-09-14 2014-01-17 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료용 디펩티딜 펩티다아제 억제제
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
PE20090213A1 (es) 2007-05-04 2009-02-28 Bristol Myers Squibb Co Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
ES2388967T3 (es) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
CA2693439A1 (en) 2007-07-17 2009-01-22 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
WO2011127106A1 (en) 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
JP2013525489A (ja) 2010-05-06 2013-06-20 ブリストル−マイヤーズ スクイブ カンパニー Ｇｐｒ１１９修飾因子としての二環式ヘテロアリール類似体
EP2566862B1 (en) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
RS54447B1 (en) 2011-01-20 2016-06-30 Bionevia Pharmaceuticals Inc. MODIFIED LABELING COMPOSITIONS OF EPALRESTAT OR ITS DERIVATIVES AND PROCEDURES FOR THEIR USE
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US10604541B2 (en) 2016-07-22 2020-03-31 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
EP0343273B1 (de) * 1988-05-27 1994-04-27 Deutsche ITT Industries GmbH Korrekturschaltung für ein digitales Quadratur-Signalpaar
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
JP3314938B2 (ja) * 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
AP9600817A0 (en) * 1995-06-06 1996-07-31 Pfizer Novel cryatal form of anhydrous 7-( [1A,5A,6A]-6-amino3-3-azabicyclo [3.1.0.] hex-3-yl) -6-fluro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt.

Also Published As

Publication number Publication date
PE135399A1 (es) 2000-01-15
HUP0100272A2 (hu) 2001-06-28
GT199800166A (es) 2000-04-19
NO20002164D0 (no) 2000-04-27
CA2310069A1 (en) 1999-06-03
SK7222000A3 (en) 2001-09-11
HRP20000327A2 (en) 2001-02-28
YU30700A (sh) 2002-12-10
AP911A (en) 2000-12-07
ZA9810636B (en) 2000-05-22
ATE205403T1 (de) 2001-09-15
TNSN98211A1 (fr) 2005-03-15
TR200001451T2 (tr) 2002-06-21
BR9814698A (pt) 2000-10-03
WO1999026659A1 (en) 1999-06-03
JP2002504478A (ja) 2002-02-12
DZ2656A1 (fr) 2003-03-22
HUP0100272A3 (en) 2002-11-28
BG104435A (bg) 2001-01-31
UY25258A1 (es) 2000-12-29
ID24524A (id) 2000-07-20
UA57811C2 (uk) 2003-07-15
DK1032424T3 (da) 2001-11-19
IL135713A0 (en) 2001-05-20
KR20010032304A (ko) 2001-04-16
OA11379A (en) 2004-01-28
GR3037071T3 (en) 2002-01-31
EP1032424B9 (en) 2004-10-06
KR20010032300A (ko) 2001-04-16
IS5453A (is) 2000-04-14
PT1032424E (pt) 2001-12-28
DE69801680T2 (de) 2002-02-07
PL340643A1 (en) 2001-02-12
AU9555898A (en) 1999-06-15
KR100661214B1 (ko) 2006-12-26
AU733304B2 (en) 2001-05-10
AP9801401A0 (en) 1998-12-31
CN1279617A (zh) 2001-01-10
EA002365B1 (ru) 2002-04-25
DE69801680D1 (de) 2001-10-18
MA26568A1 (fr) 2004-12-20
NO20002164L (no) 2000-07-19
AR016423A1 (es) 2001-07-04
EA200000433A1 (ru) 2000-12-25
EP1032424B1 (en) 2001-09-12
EP1032424A1 (en) 2000-09-06
ES2161548T3 (es) 2001-12-01

Similar Documents

Publication Publication Date Title
PA8462301A1 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
PA8493701A1 (es) Compuestos para tratar la obesidad
CR20120009A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
PA8561301A1 (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal
BR0211905A (pt) Dialdeìdos de rapamicina
GT200000038A (es) Inhibidores de la sorbitol deshidrogenasa.
HN2003000417A (es) Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
UY28691A1 (es) Derivados de difenilazetidona
ES2178291T3 (es) Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a.
UY29902A1 (es) Diarilureas para el tratamiento de la hipertensión pulmonar
UY28695A1 (es) Derivados de difenilazetidona
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
CR8111A (es) Derivados sustituidos del pirrol
PA8452701A1 (es) Agonistas de prostaglandinas
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
PA8514901A1 (es) Metabolitos agonistas/antagonistas de estrogeno
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
DE60217292D1 (de) Veterinärmedizinische dermatologische zusammensetzung